BrainCool receives FDA breakthrough device designation for Cooral System for prevention of oral mucositis

BrainCool

11 February 2021 - Recent Medicare reimbursement ruling provides an additional boost in paving the way for elimination of one of the severest side effects of cancer treatment.

BrainCool announced today that the U.S. FDA has granted breakthrough device designation for the Cooral System for the prevention of oral mucositis.

Read BrainCool press release

Michael Wonder

Posted by:

Michael Wonder